Ruptures of the carotid artery (cervical artery dissection) are the most common cause of stroke in people under 50 years of age, with an annual incidence of 2-3 cases per 100,000 persons. Salicylic-acid preparations (acetylsalicylic acid: aspirin, Aspegic) and blood-thinning medication (anticoagulants) are used for treatment. The multicenter therapy study "Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection (TREAT-CAD, NCT02046460)" investigated whether dissections - tears in the wall of vessels supplying blood to the brain - can be treated with aspirin or whether more complex blood thinning (anticoagulation) is necessary. The study was published in The Lancet Neurology on March 23, 2021.
Aspirin not equally effective
Nearly 200 patients took part in the study. The evaluation showed that in the group treated with aspirin, 23 percent had subsequent problems compared with just under 15 percent in the group treated with blood thinners. This is the first scientific study to show that in the first 90 days aspirin is not as effective as blood thinning with anticoagulation.
A broad-based study
The international study was conducted at ten centers, seven in Switzerland, two in Germany and one in Denmark. The study was led by Prof. Dr. Stefan Engelter (University Geriatric Medicine FELIX PLATTER, UAFP and University Hospital Basel, USB). He was supported by Dr. Christopher Traenka (UAFP, USB), Prof. Dr. Philippe Lyrer (USB), and Prof. Dr. Marcel Arnold (Inselspital Bern, Bern University Hospital and University of Bern).
Impact on guidelines expected
The study suggests that the evidence to consider aspirin as standard of care in patients with cervical artery dissection is insufficient. Aspirin cannot simply replace conventional standard therapy with a blood thinner. With the results of this study, however, a general superiority of blood thinning with anticoagulation has not yet been proven. The investigation of further aspects and a review of the benefit-risk profiles must provide more precise information.